TUESDAY, April 12 (HealthDay News) -- In a new study, close to a
third of patients taking the arthritis drug Humira developed an
immune system reaction to it that rendered it ineffective.
Researchers say the finding helps to explain why some people get
relief from their rheumatoid arthritis symptoms while on Humira
(adalimumab), which is made by Abbott Laboratories, while others
gain little or no benefit. Humira belongs to a class of drugs known
In those people for whom the drug is ineffective, the immune
system realizes the drug is a foreign substance and develops
antibodies to it, researchers explained. Those antibodies bind to
the drug and prevent it from working.
"What the publication shows is that Humira, like many other biologic agents, may induce an immunological response against the drug," said senior study author Dr. Gerrit Jan Wolbink, a rheumatologist at Jan van Breemen Research Institute in the Netherlands. "The immunological response works against the drug. This is one of the explanations why some patients do not respond the way we hope they will."
Patients who were also taking methotrexate, another arthritis
drug and an immunosuppressant, were less likely to develop the
antibodies, according to the study in the April 13 issue of the
Journal of the American Medical Association.
Researchers followed 272 patients taking Humira for about three
About 28 percent developed immune system antibodies against the
drug. The reaction tended to happen within the first few months of
starting treatment: About 67 percent of those who developed
antibodies did so during the first 28 weeks.
Patients without antibodies had more of the drug circulating in
their blood. Lower levels of the drug are a sign that the body's
immune system is fighting the drug and it's being removed from the
body, Jan Wolbink explained.
Whether or not patients developed antibodies was also linked to
whether they got relief from their rheumatoid arthritis while on
Nearly half -- 48 percent -- of those without antibodies
experienced a significant reduction of their arthritis symptoms
while taking the drug, while only 13 percent of those who developed
antidrug antibodies got similar relief.
And while 34 percent of patients without antibodies experienced
remission, only 4 percent of those who developed antibodies
Patients who developed antibodies were also more likely to drop
out of the study because of "treatment failure."
Humira is a tumor necrosis factor (TNF) inhibitor, which works
by blocking the action of TNF, a substance known as a cytokine that
contributes to the inflammation of rheumatoid arthritis and other
"If you make antibodies, then Humira doesn't block the action of TNF, and it doesn't work," Jan Wolbink said.
Dr. Olga Belostotsky, a rheumatologist and chief of allergy and
immunology at Lennox Hill Hospital in New York City, said the
research helps explain why some patients don't respond to Humira,
and yet they do respond when switched to another drug in the same
class of TNF inhibitors.
"It's because they don't have antibodies to the other drugs, even when it's another drug in the same group of medications," she said.
Belostotsky said the research suggests it's very important that
patients start methotrexate to suppress the immune system before
What isn't known is why those 28 percent of patients developed
antidrug antibodies while the rest didn't.
"Why antibodies develop in some people more than the others is unclear, and why people react more to some drugs than others is unclear," Belostotsky said.
Foundation has more on rheumatoid arthritis.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Publishing. All rights reserved.